摘要
白细胞介素-17 (IL-17)是一种必不可少的促炎细胞因子,主要由CD4+辅助T细胞(Th17细胞)和先天淋巴样细胞亚群分泌。IL-17与多种炎症性疾病的发病机制有关,包括银屑病、化脓性汗腺炎、毛发红糠疹、特应性皮炎、斑秃和系统性硬化症。目前已经证实IL-23/IL-17轴是炎症性疾病的靶向治疗的重要途径。来自临床试验的新证据表明,针对IL-17的单克隆抗体对治疗银屑病、化脓性汗腺炎、毛发红糠疹和系统性硬化症患者是有效的。
Interleukin-17 (IL-17), an essential pro-inflammatory cytokine, is largely released by CD4+ helper T cells (Th17 cells) and a subset of innate lymphoid cells. IL-17 has been linked to the pathogenesis of various inflammatory diseases, including psoriasis, hidradenitis suppurativa, pityriasis rubra pi-laris, atopic dermatitis, alopecia areata and systemic sclerosis. Recently, it has been demonstrated that the IL-23/IL-17 axis is a crucial approach for targeted treatments of inflammatory diseases. According to new evidence from clinical trials, monoclonal antibodies against IL-17 may be helpful in treating patients with psoriasis, hidradenitis suppurativa, pityriasis rubra pilaris and systemic sclerosis.
出处
《临床医学进展》
2023年第4期5229-5235,共7页
Advances in Clinical Medicine
